ArticleCureus2026
Predictive Modeling for Ovarian Cancer Diagnosis: Integration of Positron Emission Tomography/Computed Tomography (PET/CT) Metabolic Parameters, Clinical Risk Factors, and Serum Biomarkers.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer is often diagnosed at an advanced stage, leading to high mortality. This study aimed to develop and validate an integrated predictive model for advanced-stage (International Federation of Gynecology and Obstetrics III/IV) ovarian cancer combining positron emission tomography/computed tomography (PET/CT) metabolic parameters, clinical risk factors, and serum biomarkers in patients with histologically confirmed epithelial ovarian cancer.
methodsA retrospective cohort study was conducted among 187 patients with histologically confirmed epithelial ovarian cancer at King Hussein Medical Center (from January to December 2023). A multivariable logistic regression model was developed integrating PET/CT metabolic parameters (maximum standardized uptake value (SUVmax) and metabolic tumor volume), clinical risk factors (age, nulliparity, breast cancer gene (BRCA) status, and ascites), and serum biomarkers (cancer antigen 125 (CA-125), human epididymis protein 4). Model performance was assessed using area under the curve (AUC), sensitivity, specificity, net reclassification improvement (NRI), and decision curve analysis. Internal validation was performed using 1,000 bootstrap resamples.
resultsThe integrated model demonstrated superior discrimination for advanced-stage disease (AUC = 0.91, 95% confidence interval (CI): 0.87-0.95) compared with PET/CT alone (AUC = 0.79, p = 0.002) or clinical evaluation with CA-125 (AUC = 0.74, p < 0.001). Key independent predictors included SUVmax >10 (adjusted odds ratio (aOR) = 2.67, 95% CI: 1.48-4.82), CA-125 ≥350 U/mL (aOR = 2.35, 95% CI: 1.32-4.18), ascites (aOR = 3.78, 95% CI: 2.04-7.01), and nulliparity (aOR = 1.98, 95% CI: 1.12-3.51). High-grade serous carcinomas demonstrated significantly higher metabolic activity (median SUVmax 12.4) compared with other subtypes (p < 0.001). The full model provided a significant NRI of 19.3% over the PET/CT-plus-clinical model, with an optimism-corrected AUC of 0.89. Decision curve analysis confirmed clinical utility across the 20%- 80% threshold probabilities. Model performance was superior in BRCA mutation carriers (AUC = 0.94) vs. noncarriers (AUC = 0.85, interaction p = 0.038).
conclusionsIntegration of PET/CT metabolic parameters with clinical and biomarker variables significantly enhances prediction of advanced-stage ovarian cancer. This multivariate approach provides a foundation for preoperative risk stratification, enabling improved surgical planning and optimized referral to specialized centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.